Delivery Order SPE2DB24D2011-SPE2DB25FBRLZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,371.64 for 100 capsules of Vyvanse 60 mg on April 22, 2025, with a completion date of April 23, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The pharmaceutical will be delivered to the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,121.45 for Vyvanse 60 mg capsules (100-count units) on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a discrete transaction under AmerisourceBergen's broader federal contract portfolio...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse (lisdexamfetamine) 30mg capsules under a firm fixed-price contract with a ceiling value of $30,816.60. This delivery order, awarded on September 15, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical. The award was competitively awarded with no set-aside designation...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,139.08 for Vyvanse 10 mg capsules (100-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. This non-competitive delivery order represents a firm fixed price transaction for pharmaceutical supply to support federal medical procurement needs. The award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) valued at $9,612.42 with a firm fixed price structure. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.32 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work is to...
- The Defense Logistics Agency awarded a $2,336.95 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, a prescription medication commonly used to treat attention-deficit/hyperactivity disorder. The award was made on July 10, 2025, with an ultimate completion date of July 11, 2025, under a firm fixed-price contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, where the pharmaceutical products will be delivered, is a...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRLZDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,395.19 for Vyvanse 60 mg capsules (100-count units) on August 5, 2025, with completion targeted for August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves military and veteran healthcare systems through its extensive portfolio of pharmaceutical and medical supply deliveries. The parent IDC SPE2DX functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for Vyvrase, a controlled substance used in attention deficit treatment, reflects the contractor's role in supporting Defense Health Agency pharmaceutical requirements under the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/5/25 |